Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

DealWatch_1200x675
DEALS CONTINUE APACE IN ASIA

More from Focus On Asia

More from Scrip